

Serge Korjian

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11857219/serge-korjian-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44
papers

1,749
citations

16
h-index

41
g-index

49
ext. papers

2,173
ext. citations

6.1
avg, IF

4.11
L-index

#	Paper	IF	Citations
44	Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design.. <i>Clinical Cardiology</i> , 2022 ,	3.3	2
43	Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity.. <i>Journal of the American Heart Association</i> , 2022 , e024754	6	0
42	Digital technologies and the democratization of clinical research: Social media, wearables, and artificial intelligence.. <i>Contemporary Clinical Trials</i> , 2022 , 106767	2.3	0
41	Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis.. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 774418	5.4	1
40	Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1562-1573	7	1
39	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, f50-f60	6.4	14
38	The Impact of the COVID-19 Pandemic on Cardiovascular Fellows-in-Training: A National Survey. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 871-875	15.1	17
37	Vitamin K2 Status and Arterial Stiffness Among Untreated Migraine Patients: A Case-Control Study. <i>Headache</i> , 2020 , 60, 589-599	4.2	4
36	Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. <i>TH Open</i> , 2019 , 3, e103-e108	2.7	1
35	Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post-Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS-TIMI 46 and ATLAS ACS 2-TIMI 51. <i>Journal of the American Heart Association</i> , 2019 , 8,	6	2
34	Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. <i>Circulation</i> , 2019 , 139, 1234-1236	16.7	4
33	Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis). <i>American Journal of Cardiology</i> , 2019 , 123, 355-360	3	5
32	The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. <i>American Heart Journal</i> , 2019 , 208, 81-90	4.9	16
31	Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 186-193	4.3	9
30	Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment. <i>International Urology and Nephrology</i> , 2018 , 50, 1075-1083	2.3	17
29	Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. <i>American Heart Journal</i> , 2018 , 198, 84-90	4.9	16
28	Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. <i>TH Open</i> , 2018 , 2, e16-e24	2.7	6

27	Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 1-8	5.1	14
26	Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 2046-2052	7	28
25	Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial). <i>American Journal of Cardiology</i> , 2018 , 122, 1896-1901	3	12
24	Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors. <i>Expert Review of Cardiovascular Therapy</i> , 2017 , 15, 237-245	2.5	10
23	The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. <i>American Heart Journal</i> , 2017 , 185, 93-100	4.9	43
22	N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 457-465	5.1	8
21	Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	30
20	Vitamin K2 supplementation and arterial stiffness among renal transplant recipients-a single-arm, single-center clinical trial. <i>Journal of the American Society of Hypertension</i> , 2017 , 11, 589-597		35
19	The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. <i>TH Open</i> , 2017 , 1, e56-e65	2.7	62
18	Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. <i>Circulation</i> , 2017 , 135, 323-333	16.7	72
17	Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). <i>Circulation</i> , 2017 , 135, 648-655	16.7	46
16	Etiology of End-Stage Renal Disease and Arterial Stiffness among Hemodialysis Patients. <i>BioMed Research International</i> , 2017 , 2017, 2543262	3	9
15	Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016 , 21, 227-32	2.6	9
14	Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. <i>American Heart Journal</i> , 2016 , 152, 288-292	4.9	23
13	Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial). <i>American Journal of Cardiology</i> , 2016 , 118, 625-31	3	6
12	Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. <i>New England Journal of Medicine</i> , 2016 , 375, 2423-2434	59.2	929
11	EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. <i>European Heart Journal</i> , 2016 , 37, 1296-303	9.5	87
10	Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). <i>Circulation</i> , 2016 , 134, 1918-1930	16.7	110

9	Medical education in a foreign language and history-taking in the native language in Lebanon - a nationwide survey. <i>BMC Medical Education</i> , 2016 , 16, 298	3.3	11
8	Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9, e003114	6	12
7	Change in Pulse Wave Velocity and Short-Term Development of Cardiovascular Events in the Hemodialysis Population. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 857-63	2.3	10
6	Renal function decline in recipients and donors of kidney grafts: role of aortic stiffness. <i>American Journal of Nephrology</i> , 2015 , 41, 57-65	4.6	7
5	Dual Pathway Therapy for Secondary Prevention Following Acute Coronary Syndrome. <i>Current Cardiovascular Risk Reports</i> , 2015 , 9, 1	0.9	
4	D-Dimer elevation and adverse outcomes. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 39, 55-9	5.1	45
3	Pheochromocytoma Presenting as Partial HELLP Syndrome. <i>Case Reports in Obstetrics and Gynecology</i> , 2015 , 2015, 294326	0.8	1
2	Organ procurement: should we teach undergraduate medical and nursing students?. <i>Experimental and Clinical Transplantation</i> , 2015 , 13 Suppl 1, 55-8	0.8	
1	Outcome Of Bone Marrow Transplantation In Lebanese Children With β -Thalassemia Major. <i>Blood</i> , 2013 , 122, 5505-5505	2.2	